Abstract
The development of vaccines which induce high titres of protective antibodies has proved challenging for complex diseases such as malaria and HIV. In the case of malaria the circumsporozoite protein (CSP) antigen of Plasmodium encases the parasite and is a major vaccine candidate; however, protective antibody responses to this antigen are short-lived in vaccinated humans
Original language | English |
---|---|
Pages (from-to) | 81-82 |
Journal | European Journal of Immunology |
Volume | 49 |
Issue number | S1 |
DOIs | |
Publication status | Published - 2019 |